Live Breaking News & Updates on Duke Cancer Institute Center

Stay updated with breaking news from Duke cancer institute center. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Study Data Shows Potential of Gene Signatures to Predict Treatment Response in Patients With Recurrent Prostate Cancer

The research was aided by the Decipher Genomics Resource for Intelligent Discovery, which helped derive the gene signatures used during the analysis. ....

Andrew Armstrong , Elai Davicioni , Duke Cancer Institute Center , Decipher Genomics Resource , Intelligent Discovery , Urologic Cancers ,

Veracyte Announces that Findings Published in JCO Precision Oncology Suggest Potential of Decipher GRID-Derived Gene Signatures to Predict Treatment Response in Recurrent Prostate Cancer

New data are from a retrospective analysis of the Phase 2 STREAM trial

. ....

United States , South San Francisco , Andrew Armstrong , Elai Davicioni , Research Use , Duke University , Veracyte Inc , Duke Cancer Institute Center , Decipher Genomics Resource , Intelligent Discovery , Urologic Cancers , Research Use Only , Annual Report , Quarterly Report , For Research Use Only ,

Adding Olaparib to Abiraterone Does Not Worsen HRQoL in mCRPC

Investigators studied health-related quality of life (HRQoL) and pain outcomes for patients with metastatic prostate cancer (mCRPC) taking olaparib plus abiraterone. ....

North Carolina , United States , Andrewj Armstrong , Merck Sharp Dohme , American Society Of Clinical Oncology , Duke Cancer Institute Center , American Society , Clinical Oncology , Urologic Cancer , Functional Assessment , Cancer Therapy , Prostate Cancer , Brief Pain Inventory Short Form , Merck Sharp ,

Adding Olaparib to Abiraterone Does Not Worsen HRQoL in mCRPC

Investigators studied health-related quality of life (HRQoL) and pain outcomes for patients with metastatic prostate cancer (mCRPC) taking olaparib plus abiraterone. ....

United States , North Carolina , Andrewj Armstrong , Duke Cancer Institute Center , American Society Of Clinical Oncology , American Society , Clinical Oncology , Urologic Cancer , Functional Assessment , Cancer Therapy , Prostate Cancer , Brief Pain Inventory Short Form ,

New drug combo shows promise against prostate cancer in trials

In a phase 3 clinical trial by Pfizer, treatment with talazoparib and enzalutamide lowered the risk of prostate cancer progression or death by 37%. ....

Andrewj Armstrong , Coran Sternberg , Scottt Tagawa , Nicholas Zorko , Duke Cancer Institute Center , Masonic Cancer Center , University Of Minnesota , Urologic Cancers , Weill Cornell Medicine , Medical News Today ,